Trial Summary
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
The research suggests that targeting oncostatin M (OSM), a molecule involved in cancer growth and spread, could help reduce aggressive cancer behavior and therapy failure, which might be relevant to the effectiveness of IMM-6-415 if it targets similar pathways.
12345AMG 232, which may be related to IMM-6-415, was tested in a study with patients having advanced solid tumors or multiple myeloma. It was generally safe up to a dose of 240 mg, with some patients experiencing mild to moderate side effects like diarrhea, nausea, and fatigue. Serious side effects included low platelet counts (thrombocytopenia) and low white blood cell counts (neutropenia).
678910Eligibility Criteria
This trial is for adults with advanced or metastatic solid tumors, like melanoma and lung cancer, that have specific genetic changes called RAS or RAF mutations. Participants should not have had prior treatment with IMM-6-415.Inclusion Criteria
Exclusion Criteria